Minimal Residual Disease (MRD) Status Predicts Outcomes in Patients with Follicular Lymphoma (FL) Treated with Chemo-Immunotherapy on SWOG S0016

被引：0
|
作者：
Danilov, Alexey [1 ]
Li, Hongli [2 ]
Shadman, Mazyar [2 ]
Rimsza, Lisa M. [3 ]
Zebari, Ahmad [2 ]
Smith, Sonali M. [4 ]
Leblanc, Michael [2 ]
Friedberg, Jonathan W. [5 ]
Carlson, Christopher [2 ]
Song, Joo Y. [6 ]
机构：
[1] City Hope Natl Med Ctr, Dept Hematol & HCT, La Canada Flintridge, CA USA
[2] Fred Hutchinson Canc Ctr, Seattle, WA USA
[3] Mayo Clin Scottsdale, Scottsdale, AZ USA
[4] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL USA
[5] Univ Rochester, Wilmot Canc Ctr, Rochester, NY USA
[6] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-179612
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 35 条
  • [1] Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016
    Qu, Xiaoyu
    Li, Hongli
    Press, Oliver W.
    Rimsza, Lisa M.
    Braziel, Rita M.
    Leblanc, Michael
    Hsi, Eric D.
    Smith, Sonali M.
    Friedberg, Jonathan W.
    Fang, Min
    [J]. BLOOD, 2015, 126 (23)
  • [2] Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016
    Qu, Xiaoyu
    Li, Hongli
    Braziel, Rita M.
    Passerini, Verena
    Rimsza, Lisa M.
    Hsi, Eric D.
    Leonard, John P.
    Smith, Sonali M.
    Kridel, Robert
    Press, Oliver
    Weigert, Oliver
    LeBlanc, Michael
    Friedberg, Jonathan W.
    Fang, Min
    [J]. BLOOD, 2019, 133 (01) : 81 - 93
  • [3] Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016
    Qu, Xiaoyu
    Li, Hongli
    Press, Oliver W.
    Rimsza, Lisa M.
    Braziel, Rita M.
    Leblanc, Michael L.
    Hsi, Eric D.
    Leonard, John P.
    Smith, Sonali M.
    Friedberg, Jonathan W.
    Fang, Min
    [J]. BLOOD, 2017, 130
  • [4] Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?
    Gritti, Giuseppe
    Pavoni, Chiara
    Rambaldi, Alessandro
    [J]. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2017, 9
  • [5] Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab
    Hirt, C
    Schüler, F
    Dölken, G
    [J]. SEMINARS IN CANCER BIOLOGY, 2003, 13 (03) : 223 - 231
  • [6] Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)
    Fulton, Noreen
    Johnson, Jeffrey
    Kaplan, Lawrence D.
    Koval, Greg
    Malnassy, Greg
    Jung, Sin-Ho
    Devine, Steve
    Shea, Thomas C.
    Leonard, John P.
    Cheson, Bruce D.
    Stock, Wendy
    [J]. BLOOD, 2013, 122 (21)
  • [7] Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016
    Burack, Richard
    Li, Hongli
    Spence, Janice M.
    Adlowitz, Diana
    Rimsza, Lisa M.
    Braziel, Rita M.
    Spier, Catherine M.
    Kaminski, Mark S.
    Leonard, John P.
    Fisher, Richard I.
    Leblanc, Michael L.
    Smith, Sonali M.
    Friedberg, Jonathan W.
    [J]. BLOOD, 2018, 132
  • [8] Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
    Pott, Christiane
    Jurinovic, Vindi
    Trotman, Judith
    Kehden, Britta
    Unterhalt, Michael
    Herold, Michael
    van der Jagt, Richard
    Janssens, Ann
    Kneba, Michael
    Mayer, Jiri
    Young, Moya
    Schmidt, Christian
    Knapp, Andrea
    Nielsen, Tina
    Brown, Helen
    Spielewoy, Nathalie
    Harbron, Chris
    Bottos, Alessia
    Mundt, Kirsten
    Marcus, Robert
    Hiddemann, Wolfgang
    Hoster, Eva
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (05)
  • [9] Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease
    Yazdy, Maryam Sarraf
    Jarral, Umair
    Yin, Chao
    Kuhr, Frank
    Jacob, Allison P.
    Cheson, Bruce D.
    [J]. BLOOD, 2019, 134
  • [10] A brief course of chemo-immunotherapy FND plus rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis.
    Vitolo, U
    Boccomini, C
    Ladetto, M
    Pogliani, E
    Scalabrini, DR
    Tarella, C
    Castellino, C
    Aglietta, M
    Astolfi, M
    Botto, B
    Carpaneto, A
    Corradini, P
    Darbesio, A
    De Crescenzo, A
    Levis, A
    Liberati, AM
    Morandi, S
    Orsucci, L
    Rigacci, L
    Rossini, F
    Tonso, A
    Gallo, E
    [J]. BLOOD, 2003, 102 (11) : 400A - 400A
1234